|
Liver Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 328 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Liver Cancer - Pipeline Review, H1 2012', provides an overview of the Liver Cancer therapeutic pipeline. This report provides information on the therapeutic dev.....
Introduction Global Markets Direct’s, 'Liver Cancer - Pipeline Review, H1 2012', provides an overview of the Liver Cancer therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. 'Liver Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Liver Cancer. - A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Liver Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Liver Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 11 Introduction 12 Global Markets Direct Report Coverage 12 Liver Cancer Overview 13 Therapeutics Development 14 An Overview of Pipeline Products for Liver Cancer 14 Liver Cancer Therapeutics under Development by Companies 16 Liver Cancer Therapeutics under Investigation by Universities/Institutes 24 Late Stage Products 37 Comparative Analysis 37 Mid Clinical Stage Products 38 Comparative Analysis 38 Early Clinical Stage Products 39 Comparative Analysis 39 Discovery and Pre-Clinical Stage Products 40 Comparative Analysis 40 Liver Cancer Therapeutics – Products under Development by Companies 41 Liver Cancer Therapeutics – Products under Investigation by Universities/Institutes 51 Companies Involved in Liver Cancer Therapeutics Development 76 Bristol-Myers Squibb Company 76 Boehringer Ingelheim GmbH 77 F. Hoffmann-La Roche Ltd. 78 Celsion Corporation 79 Abbott Laboratories 80 Biogen Idec Inc. 81 Amgen Inc. 82 Sanofi-Aventis 83 AstraZeneca PLC 84 Eli Lilly and Company 85 GlaxoSmithKline plc 86 Tekmira Pharmaceuticals Corp. 87 Daiichi Sankyo Company, Ltd 88 YM BioSciences Inc. 89 Light Sciences Oncology, Inc. 90 ZIOPHARM Oncology, Inc. 91 Novartis AG 92 Samyang Corporation 93 ImClone Systems Incorporated 94 Chugai Pharmaceutical Co. Ltd 95 Eisai Co., Ltd. 96 Human Genome Sciences, Inc. 97 Kowa Company, Ltd. 98 MDRNA, Inc. 99 OSI Pharmaceuticals, Inc. 100 Pfizer Inc. 101 SuperGen, Inc. 102 Taiho Pharmaceutical Co., Ltd. 103 Hadasit Medical Research Services & Development Ltd 104 Exelixis, Inc. 105 Bayer AG 106 4SC AG 107 Celldex Therapeutics, Inc. 108 Can-Fite BioPharma Ltd. 109 Ligand Pharmaceuticals Incorporated 110 Neuren Pharmaceuticals Limited 111 NexMed, Inc. 112 Northwest Biotherapeutics, Inc. 113 Novogen Limited 114 Cleveland BioLabs, Inc. 115 OXiGENE, Inc. 116 Patrys Limited 117 Peregrine Pharmaceuticals, Inc. 118 Curis, Inc. 119 ARQULE, INC 120 Alnylam Pharmaceuticals, Inc 121 Transgene SA 122 Sirtex Medical Limited 123 Immuron Limited 124 Progen Pharmaceuticals Limited 125 Innocell Corporation 126 Jiangsu Hengrui Medicine Co., Ltd. 127 Provectus Pharmaceuticals, Inc. 128 Synta Pharmaceuticals Corp. 129 CrystalGenomics, Inc. 130 BioAlliance Pharma SA 131 Raptor Pharmaceuticals Corp. 132 RXi Pharmaceuticals Corporation 133 SymBio Pharmaceuticals Limited 134 ERYtech Pharma 135 Provecs Medical GmbH 136 TMRC Co., Ltd. 137 Pharmascience Inc. 138 Mondobiotech Holding AG 139 Celecure AS 140 Reata Pharmaceuticals, Inc. 141 Jennerex Biotherapeutics, Inc. 142 Advenchen Laboratories, LLC 143 AndroScience Corporation 144 Onconova Therapeutics, Inc 145 MolMed S.p.A. 146 PhytoCeutica, Inc. 147 Mirna Therapeutics, Inc. 148 China Medical System Holdings Limited 149 Welichem Biotech Inc. 150 Oncolys BioPharma Inc. 151 Immunocore Limited. 152 Sirnaomics, Inc. 153 CureTech Ltd. 154 Viventia Biotechnologies Inc. 155 Vicus Therapeutics, LLC 156 TRACON Pharmaceuticals, Inc. 157 KAHR medical Ltd. 158 Regulus Therapeutics Inc. 159 Direct Therapeutics, Inc. 160 KAEL-GemVax 161 Therapure Biopharma Inc. 162 VectorLogics, Inc. 163 Polaris Group 164 IkerChem S.L. 165 Liver Cancer – Therapeutics Assessment 166 Assessment by Monotherapy Products 166 Assessment by Combination Products 167 Assessment by Route of Administration 168 Assessment by Molecule Type 171 Drug Profiles 174 BMS-582664 - Drug Profile 174 Nexavar - Drug Profile 176 ABT-869 - Drug Profile 177 Livatag - Drug Profile 179 Paclitaxel - Drug Profile 181 Afinitor - Drug Profile 182 IMC-1121B - Drug Profile 184 Thermodox - Drug Profile 186 Muparfostat - Drug Profile 188 TSU68 - Drug Profile 190 NIK-333 - Drug Profile 191 Aptocine - Drug Profile 192 SIR-Spheres Microspheres + FOLFOX - Drug Profile 194 PrevOnco + Doxorubicin - Drug Profile 196 Eloxatin + 5-Fluorouracil + Leucovorin - Drug Profile 197 Carboplatin + Cisplatin + Doxorubicin Hydrochloride - Drug Profile 199 Cisplatin + Doxorubicin Hydrochloride - Drug Profile 201 Oxaliplatin + Capecitabine - Drug Profile 203 Xeloda - Drug Profile 204 Sodium Thiosulfate - Drug Profile 205 Sorafenib + Transarterial Chemoembolisation - Drug Profile 206 ADI-PEG 20 - Drug Profile 207 FOLFOX - Drug Profile 209 PrevOnco - Drug Profile 210 Eloxatin + 5-FU + Leucovorin - Drug Profile 211 Nexavar + Tarceva - Drug Profile 213 Fotemustine - Drug Profile 214 Oxaliplatin + Leucovorin + 5-Fluorouracil - Drug Profile 215 Fluorouracil + Leucovorin - Drug Profile 217 Fluorouracil + Leucovorin Calcium 1 - Drug Profile 218 FOLFOX4 - Drug Profile 219 Floxuridine + Oxaliplatin + Capecitabine - Drug Profile 220 Oxaliplatin + Fluorouracil + Leucovorin Calcium - Drug Profile 222 Oxaliplatin + Fluorouracil + Leucovorin Calcium + Cetuximab - Drug Profile 224 Oxaliplatin + Capecitabine - Drug Profile 226 Oxaliplatin + Capecitabine + Cetuximab - Drug Profile 228 FOLFIRI + Melphalan + Floxuridine - Drug Profile 230 Sirolimus - Drug Profile 232 Thymopentin - Drug Profile 233 Doxorubicin + Sorafenib - Drug Profile 234 Sirolimus - Drug Profile 236 Cisplatin + Carboplatin + Doxorubicin - Drug Profile 237 Cisplatin + Doxorubicin + Mitomycin C + Sorafenib - Drug Profile 239 Immuncell-LC - Drug Profile 241 Sirolimus - Drug Profile 242 Sorafenib - Drug Profile 243 Xelox + Bevacizumab - Drug Profile 244 TACE + Sunitinib Malate - Drug Profile 245 Tarceva - Drug Profile 246 Leucovorin + Tegafur + Uracil - Drug Profile 248 Doxorubicin + Mitomycin + Cisplatin - Drug Profile 249 cisplatin - Drug Profile 251 Oxaliplatin + 5-Fluorouracil + Leucovorin - Drug Profile 252 Cisplatin + Doxorubicin Hydrochloride + Fluorouracil + Irinotecan Hydrochloride + Vincristine Sulfate - Drug Profile 253 Cisplatin + Doxorubicin Hydrochloride + Fluorouracil + Vincristine Sulfate - Drug Profile 255 Cisplatin + Fluorouracil + Vincristine Sulfate - Drug Profile 257 Thalidomide + TACE - Drug Profile 258 vincristine + fluorouracil + amifostine + amifostine - Drug Profile 259 Octreotide-LAR + Lanreotide Autogel - Drug Profile 261 Cytokine-Induced Killer Cell (CIK) - Drug Profile 263 Sorafenib + Pravastatin - Drug Profile 264 Adefovir Dipivoxil + Lamivudine - Drug Profile 265 Sorafenib + Cisplatin + Fluorouracil - Drug Profile 266 Gemcitabine + Capecitabine - Drug Profile 268 Gemcitabine Hydrochloride + Oxaliplatin - Drug Profile 270 FOLFOX6 + Sir-Spheres Microspheres + Avastin - Drug Profile 271 Eloxatin + Capecitabine + Sorafenib - Drug Profile 273 Sunitinib + Chemoembolization - Drug Profile 275 S-1 - Drug Profile 276 Doxorubicin Eluting Beads + Sorafenib - Drug Profile 277 Aptocine + FOLFIRI - Drug Profile 278 Aptocine + FOLFOX4 - Drug Profile 280 Gemox 85 - Drug Profile 282 Liver Cancer Therapeutics – Drug Profile Updates 283 Liver Cancer Therapeutics – Discontinued Products 296 Liver Cancer Therapeutics - Dormant Products 300 Liver Cancer – Product Development Milestones 314 Featured News & Press Releases 314 Appendix 322 Methodology 322 Expert Panel Validation 323 Contact Us 323 Disclaimer 323 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Liver Cancer, H1 2012 19 Products under Development for Liver Cancer – Comparative Analysis, H1 2012 20 Number of Products under Development by Companies, H1 2012 22 Number of Products under Development by Companies, H1 2012 (Contd..1) 23 Number of Products under Development by Companies, H1 2012 (Contd..2) 24 Number of Products under Development by Companies, H1 2012 (Contd..3) 25 Number of Products under Development by Companies, H1 2012 (Contd..4) 26 Number of Products under Development by Companies, H1 2012 (Contd..5) 27 Number of Products under Development by Companies, H1 2012 (Contd..6) 28 Number of Products under Investigation by Universities/Institutes, H1 2012 30 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 31 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 32 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 33 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 34 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 35 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 36 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 37 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 38 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 39 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 40 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 41 Comparative Analysis by Late Stage Development, H1 2012 42 Comparative Analysis by Mid Clinical Stage Development, H1 2012 43 Comparative Analysis by Early Clinical Stage Development, H1 2012 44 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 45 Products under Development by Companies, H1 2012 46 Products under Development by Companies, H1 2012 (Contd..1) 47 Products under Development by Companies, H1 2012 (Contd..2) 48 Products under Development by Companies, H1 2012 (Contd..3) 49 Products under Development by Companies, H1 2012 (Contd..4) 50 Products under Development by Companies, H1 2012 (Contd..5) 51 Products under Development by Companies, H1 2012 (Contd..6) 52 Products under Development by Companies, H1 2012 (Contd..7) 53 Products under Development by Companies, H1 2012 (Contd..8) 54 Products under Development by Companies, H1 2012 (Contd..9) 55 Products under Investigation by Universities/Institutes, H1 2012 56 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 69 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 70 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 71 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 72 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 73 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 74 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 75 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 76 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 77 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 78 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 79 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 80 Bristol-Myers Squibb Company, H1 2012 81 Boehringer Ingelheim GmbH, H1 2012 82 F. Hoffmann-La Roche Ltd., H1 2012 83 Celsion Corporation, H1 2012 84 Abbott Laboratories, H1 2012 85 Biogen Idec Inc., H1 2012 86 Amgen Inc., H1 2012 87 Sanofi-Aventis, H1 2012 88 AstraZeneca PLC, H1 2012 89 Eli Lilly and Company, H1 2012 90 GlaxoSmithKline plc, H1 2012 91 Tekmira Pharmaceuticals Corp., H1 2012 92 Daiichi Sankyo Company, Ltd, H1 2012 93 YM BioSciences Inc., H1 2012 94 Light Sciences Oncology, Inc., H1 2012 95 ZIOPHARM Oncology, Inc., H1 2012 96 Novartis AG, H1 2012 97 Samyang Corporation, H1 2012 98 ImClone Systems Incorporated, H1 2012 99 Chugai Pharmaceutical Co. Ltd, H1 2012 100 Eisai Co., Ltd., H1 2012 101 Human Genome Sciences, Inc., H1 2012 102 Kowa Company, Ltd., H1 2012 103 MDRNA, Inc., H1 2012 104 OSI Pharmaceuticals, Inc., H1 2012 105 Pfizer Inc., H1 2012 106 SuperGen, Inc., H1 2012 107 Taiho Pharmaceutical Co., Ltd., H1 2012 108 Hadasit Medical Research Services & Development Ltd, H1 2012 109 Exelixis, Inc., H1 2012 110 Bayer AG, H1 2012 111 4SC AG, H1 2012 112 Celldex Therapeutics, Inc., H1 2012 113 Can-Fite BioPharma Ltd., H1 2012 114 Ligand Pharmaceuticals Incorporated, H1 2012 115 Neuren Pharmaceuticals Limited, H1 2012 116 NexMed, Inc., H1 2012 117 Northwest Biotherapeutics, Inc., H1 2012 118 Novogen Limited, H1 2012 119 Cleveland BioLabs, Inc., H1 2012 120 OXiGENE, Inc., H1 2012 121 Patrys Limited, H1 2012 122 Peregrine Pharmaceuticals, Inc., H1 2012 123 Curis, Inc., H1 2012 124 ARQULE, INC, H1 2012 125 Alnylam Pharmaceuticals, Inc, H1 2012 126 Transgene SA, H1 2012 127 Sirtex Medical Limited, H1 2012 128 Immuron Limited, H1 2012 129 Progen Pharmaceuticals Limited, H1 2012 130 Innocell Corporation, H1 2012 131 Jiangsu Hengrui Medicine Co., Ltd., H1 2012 132 Provectus Pharmaceuticals, Inc., H1 2012 133 Synta Pharmaceuticals Corp., H1 2012 134 CrystalGenomics, Inc., H1 2012 135 BioAlliance Pharma SA, H1 2012 136 Raptor Pharmaceuticals Corp., H1 2012 137 RXi Pharmaceuticals Corporation, H1 2012 138 SymBio Pharmaceuticals Limited, H1 2012 139 ERYtech Pharma, H1 2012 140 Provecs Medical GmbH, H1 2012 141 TMRC Co., Ltd., H1 2012 142 Pharmascience Inc., H1 2012 143 Mondobiotech Holding AG, H1 2012 144 Celecure AS, H1 2012 145 Reata Pharmaceuticals, Inc., H1 2012 146 Jennerex Biotherapeutics, Inc., H1 2012 147 Advenchen Laboratories, LLC, H1 2012 148 AndroScience Corporation, H1 2012 149 Onconova Therapeutics, Inc, H1 2012 150 MolMed S.p.A., H1 2012 151 PhytoCeutica, Inc., H1 2012 152 Mirna Therapeutics, Inc., H1 2012 153 China Medical System Holdings Limited, H1 2012 154 Welichem Biotech Inc., H1 2012 155 Oncolys BioPharma Inc., H1 2012 156 Immunocore Limited., H1 2012 157 Sirnaomics, Inc., H1 2012 158 CureTech Ltd., H1 2012 159 Viventia Biotechnologies Inc., H1 2012 160 Vicus Therapeutics, LLC, H1 2012 161 TRACON Pharmaceuticals, Inc., H1 2012 162 KAHR medical Ltd., H1 2012 163 Regulus Therapeutics Inc., H1 2012 164 Direct Therapeutics, Inc., H1 2012 165 KAEL-GemVax, H1 2012 166 Therapure Biopharma Inc., H1 2012 167 VectorLogics, Inc., H1 2012 168 Polaris Group, H1 2012 169 IkerChem S.L., H1 2012 170 Assessment by Monotherapy Products, H1 2012 171 Assessment by Combination Products, H1 2012 172 Assessment by Stage and Route of Administration, H1 2012 175 Assessment by Molecule Type, H1 2012 178 Liver Cancer Therapeutics – Drug Profile Updates 288 Liver Cancer Therapeutics – Discontinued Products 301 Liver Cancer Therapeutics – Discontinued Products (Contd..1) 302 Liver Cancer Therapeutics – Discontinued Products (Contd..2) 303 Liver Cancer Therapeutics – Discontinued Products (Contd..3) 304 Liver Cancer Therapeutics – Dormant Products 305 Liver Cancer Therapeutics – Dormant Products (Contd..1) 306 Liver Cancer Therapeutics – Dormant Products (Contd..2) 307 Liver Cancer Therapeutics – Dormant Products (Contd..3) 308 Liver Cancer Therapeutics – Dormant Products (Contd..4) 309 Liver Cancer Therapeutics – Dormant Products (Contd..5) 310 Liver Cancer Therapeutics – Dormant Products (Contd..6) 311 Liver Cancer Therapeutics – Dormant Products (Contd..7) 312 Liver Cancer Therapeutics – Dormant Products (Contd..8) 313 Liver Cancer Therapeutics – Dormant Products (Contd..9) 314 Liver Cancer Therapeutics – Dormant Products (Contd..10) 315 Liver Cancer Therapeutics – Dormant Products (Contd..11) 316 Liver Cancer Therapeutics – Dormant Products (Contd..12) 317 Liver Cancer Therapeutics – Dormant Products (Contd..13) 318 List of Figures Number of Products under Development for Liver Cancer, H1 2012 19 Products under Development for Liver Cancer – Comparative Analysis, H1 2012 20 Products under Development by Companies, H1 2012 21 Products under Investigation by Universities/Institutes, H1 2012 29 Late Stage Products, H1 2012 42 Mid Clinical Stage Products, H1 2012 43 Early Clinical Stage Products, H1 2012 44 Discovery and Pre-Clinical Stage Products, H1 2012 45 Assessment by Monotherapy Products, H1 2012 171 Assessment by Combination Products, H1 2012 172 Assessment by Route of Administration, H1 2012 173 Assessment by Stage and Route of Administration, H1 2012 174 Assessment by Molecule Type, H1 2012 176 Assessment by Stage and Molecule Type, H1 2012 177 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
